Literature DB >> 30415473

Relationship between timing of trial randomization, protocol completion, and clinical outcomes among patients hospitalized for heart failure: from the ASTRONAUT trial.

Stephen J Greene1, Gregg C Fonarow2, Scott D Solomon3, Haris P Subacius4, Muthiah Vaduganathan3, Andrew P Ambrosy5,6, Marat Fudim1, Michael Böhm7, Aldo P Maggioni8, Eldrin F Lewis3, Faiez Zannad9, Javed Butler10.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30415473      PMCID： PMC6298803          DOI： 10.1002/ejhf.1310

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN： 1388-9842            Impact factor:   15.534


× No keyword cloud information.
  9 in total

1.  Clinical trials in acute heart failure: beginning of the end or end of the beginning?

Authors:  Andrew P Ambrosy; Javed Butler; Mihai Gheorghiade
Journal:  Eur J Heart Fail       Date:  2017-06-28       Impact factor: 15.534

Review 2.  Past, present, and future of acute heart failure clinical trials-a high-risk population in search of a strategy.

Authors:  Javed Butler; Norman Stockbridge; Mihai Gheorghiade
Journal:  Eur J Heart Fail       Date:  2017-09-18       Impact factor: 15.534

3.  Rationale and design of the multicentre, randomized, double-blind, placebo-controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT).

Authors:  Mihai Gheorghiade; Mazen Albaghdadi; Faiez Zannad; Gregg C Fonarow; Michael Böhm; Claudio Gimpelewicz; Jaco Botha; Shelley Moores; Eldrin F Lewis; Henning Rattunde; Aldo Maggioni
Journal:  Eur J Heart Fail       Date:  2010-11-30       Impact factor: 15.534

4.  Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes.

Authors:  Marco Metra; Gad Cotter; Beth A Davison; G Michael Felker; Gerasimos Filippatos; Barry H Greenberg; Piotr Ponikowski; Elaine Unemori; Adriaan A Voors; Kirkwood F Adams; Maria I Dorobantu; Liliana Grinfeld; Guillaume Jondeau; Alon Marmor; Josep Masip; Peter S Pang; Karl Werdan; Margaret F Prescott; Christopher Edwards; Sam L Teichman; Angelo Trapani; Christopher A Bush; Rajnish Saini; Christoph Schumacher; Thomas Severin; John R Teerlink
Journal:  J Am Coll Cardiol       Date:  2013-01-15       Impact factor: 24.094

5.  Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.

Authors:  Marvin A Konstam; Mihai Gheorghiade; John C Burnett; Liliana Grinfeld; Aldo P Maggioni; Karl Swedberg; James E Udelson; Faiez Zannad; Thomas Cook; John Ouyang; Christopher Zimmer; Cesare Orlandi
Journal:  JAMA       Date:  2007-03-25       Impact factor: 56.272

6.  Rationale for and design of the TRUE-AHF trial: the effects of ularitide on the short-term clinical course and long-term mortality of patients with acute heart failure.

Authors:  Milton Packer; Richard Holcomb; William T Abraham; Stefan Anker; Kenneth Dickstein; Gerasimos Filippatos; Henry Krum; Aldo P Maggioni; John J V McMurray; Alexandre Mebazaa; Christopher O'Connor; Frank Peacock; Piotr Ponikowski; Frank Ruschitzka; Dirk J van Veldhuisen; Johannes Holzmeister
Journal:  Eur J Heart Fail       Date:  2016-11-13       Impact factor: 15.534

7.  Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial.

Authors:  Mihai Gheorghiade; Michael Böhm; Stephen J Greene; Gregg C Fonarow; Eldrin F Lewis; Faiez Zannad; Scott D Solomon; Fabio Baschiera; Jaco Botha; Tsushung A Hua; Claudio R Gimpelewicz; Xavier Jaumont; Anastasia Lesogor; Aldo P Maggioni
Journal:  JAMA       Date:  2013-03-20       Impact factor: 56.272

8.  Outpatient Worsening Heart Failure as a Target for Therapy: A Review.

Authors:  Stephen J Greene; Robert J Mentz; G Michael Felker
Journal:  JAMA Cardiol       Date:  2018-03-01       Impact factor: 14.676

9.  Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF-2 study.

Authors:  John R Teerlink; Adriaan A Voors; Piotr Ponikowski; Peter S Pang; Barry H Greenberg; Gerasimos Filippatos; G Michael Felker; Beth A Davison; Gad Cotter; Claudio Gimpelewicz; Leandro Boer-Martins; Margaret Wernsing; Tsushung A Hua; Thomas Severin; Marco Metra
Journal:  Eur J Heart Fail       Date:  2017-04-28       Impact factor: 15.534
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.